| Report Code: 40215 | Report Type: Competitive Landscape Reports | Pages: 150+ | Available format: |
| Therapeutic Area(s): | Neurology |
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 By industry participant
2.2.1.2 By company type
Chapter 3. Executive Summary
Chapter 4. Pipeline Outlook
4.1 Disease Overview
4.2 Sign & Symptoms
4.3 Epidemiology
4.4 Causes
4.5 Diagnosis
4.6 Prevention and Treatment
4.7 Key Drivers
4.7.1 Driver 1
4.7.2 Driver 2
4.8 Key Barriers
4.8.1 Barrier 1
4.9 RLS Therapeutics Pipeline Analysis
4.9.1 Pipeline Analysis by Phase
4.9.2 Pipeline Analysis by Molecule Type
4.9.3 Pipeline Analysis by Route of Administration
4.9.4 Pipeline Analysis by Company
Chapter 5. RLS Therapeutics Pipeline Analysis by Phase (2018)
5.1 Phase III
5.1.1 NLS-2
5.2 Phase II
5.2.1 BP1.4979
5.2.1.1 Clinical trials
5.2.2 Xxxx
5.2.2.1 Clinical trials
5.2.2.2 Clinical trials results
5.2.3 Xxxx
5.2.3.1 Clinical trials
5.2.3.2 Strategic development
5.2.3.3 Technology
5.2.4 Xxxx
5.2.4.1 Clinical trials
5.2.4.2 Strategic development
5.2.5 Xxxx
5.2.5.1 Clinical trials
5.2.5.2 Technology
5.3 Pre-Clinical
5.3.1 OMS527
5.3.1.1 Strategic development
5.3.2 Xxxx
5.3.2.1 Clinical trials
5.3.2.2 Technology
Chapter 6. Clinical Trials Review
6.1 Clinical Trials by Region
6.2 Clinical Trials by Trial Status
Chapter 7. Competitive Landscape
7.1 Key Player Benchmarking for RLS Therapeutics Pipeline
7.2 SWOT Analysis of RLS Therapeutics Pipeline
Chapter 8. Company Profiles
8.1 NLS Pharma Group
8.1.1 Business Overview
8.1.2 Product Offerings
8.2 Xxxx
8.2.1 Business Overview
8.2.2 Product Offerings
8.3 Xxxx
8.3.1 Business Overview
8.3.2 Product Offerings
8.4 Xxxx
8.4.1 Business Overview
8.4.2 Product Offerings
8.5 Xxxx
8.5.1 Business Overview
8.5.2 Product Offerings
8.6 Xxxx
8.6.1 Business Overview
8.6.2 Product Offerings
Chapter 9. Appendix
9.1 Abbreviations
9.2 Related Reports
List of Tables
TABLE 1 PIPELINE ANALYSIS OF RLS THERAPEUTICS, BY COMPANY (2018)
TABLE 2 DESCRIPTION OF NLS-2
TABLE 3 DESCRIPTION OF XXXX
TABLE 4 DESCRIPTION OF XXXX
TABLE 5 CLINICAL TRIALS OF XXXX
TABLE 6 DESCRIPTION OF XXXX
TABLE 7 DESCRIPTION OF XXXX
TABLE 8 DESCRIPTION OF XXXX
TABLE 9 CLINICAL TRIALS OF XXXX
TABLE 10 DESCRIPTION OF OMS527
TABLE 11 DESCRIPTION OF XXXX
TABLE 12 NLS PHARMA GROUP - AT A GLANCE
TABLE 13 XXXX – AT A GLANCE
TABLE 14 XXXX – AT A GLANCE
TABLE 15 XXXX – AT A GLANCE
TABLE 16 XXXX – AT A GLANCE
TABLE 17 XXXX – AT A GLANCE
List of Figures
FIG 1: RESEARCH METHODOLOGY
FIG 2: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT
FIG 3: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE
FIG 4: RLS DRUG CANDIDATES IN DEVELOPMENT (2018)
FIG 5: RLS PIPELINE SPLIT, BY MOLECULE TYPE (2018)
FIG 6: RLS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)
FIG 7: BREAKDOWN OF CLINICAL TRIALS, BY REGION
FIG 8: BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS
FIG 9: KEY PLAYER BENCHMARKING
FIG 10: SWOT ANALYSIS